Niemann-Pick Disease Type CPhase 2/3HARBORNCT07885917
Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
A Phase 2/3 study testing AZ-3102 in people with Niemann-Pick Disease Type C and GM2 Gangliosidosis, run by Azafaros B.V..
Trial summary
This is an open-label extension trial to evaluate the long-term safety and tolerability of nizubaglustat (AZ-3102) in participants with rare lysosomal disorders who have participated in a previous nizubaglustat trial and wish to continue nizubaglustat treatment. Read more about this study
- Who is it for?
- Ages 4 years and older
- Conditions the study is for
- Niemann-Pick Disease Type C, GM2 Gangliosidosis, GM1 Gangliosidosis
- What is being tested?
- AZ-3102
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 218 participants
- Where
- No sites listed yet
- Study dates
- 10 Dec 2026to 1 Apr 2030
- Phase
- Phase 2/3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Have participated in a trial of nizubaglustat and wish to continue nizubaglustat treatment
- Participation is considered beneficial by the investigator
- Female participants of childbearing potential who are willing to follow the protocol-defined contraceptive requirements
- Male participants who are willing to follow the protocol-defined contraceptive requirements
Who cannot join
- A positive serum pregnancy test (for women of childbearing potential).
- Any medical event or condition that prevents participation in the trial based on the judgment of the investigator (e.g., severe infection and severe cognitive impairment).
- Use of any other treatment with a similar mode of action to nizubaglustat (GCS or NLGase inhibition), e.g., miglustat or venglustat.
- Participation in another interventional trial or non-interventional study or in an Early Access Program.
About this study
Official title: An Open-label, Roll-over Trial to Evaluate the Long-term Safety and Tolerability of Nizubaglustat (AZ-3102) in Participants With Rare Lysosomal Disorders Who Have Participated in Previous Nizubaglustat Trials and Wish to Continue Nizubaglustat Treatment
This is an open-label extension trial to evaluate the long-term safety and tolerability of nizubaglustat (AZ-3102) in participants with rare lysosomal disorders who have participated in a previous nizubaglustat trial and wish to continue nizubaglustat treatment.
Read the detailed description
This is a multi-center, global, open-label, extension trial in participants with Niemann-Pick disease type C (NPC), GM1 gangliosidosis, GM2 gangliosidosis, or Gaucher disease type 3 (GD3) who previously participated in a clinical trial of nizubaglustat (AZ-3102) and wish to continue treatment. All participants will receive nizubaglustat once daily.
The primary objective is to assess the long-term safety and tolerability of continued daily administration of nizubaglustat. The trial will also investigate the effect of nizubaglustat on disease biomarkers and explore the effect of long-term treatment on neurological aspects of disease progression.
Participants may remain in the trial under marketing authorization has been granted for nizubaglustat in their country or until the sponsor decides to stop the trial.
- Conditions
- Niemann-Pick Disease Type C, GM2 Gangliosidosis, GM1 Gangliosidosis, Gaucher Disease Type 3
- Being tested
- AZ-3102
- Keywords
- NPC, GM1, GM2, GD3, Nizubaglustat, HARBOR, Rare Lysosomal Disorders, AZ-3102, GM1 gangliosidosis, GM2 gangliosidosis, Gaucher Disease Type 3, Niemann-Pick disease type C
- Medical subject headings
- Niemann-Pick Disease, Type C, Gangliosidoses, GM2, Gangliosidosis, GM1, Gaucher Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AZ-3102Drug
Daily oral intake of nizubaglustat (AZ-3102) dispersible tablets
| Study group | Role | What they receive |
|---|---|---|
| All participants will receive nizubaglustat | Experimental | Not described Receives: Drug: AZ-3102 |
What is being measured
The primary outcome is the main question the study is designed to answer.
The Incidence and severity of treatment-emergent adverse events (TEAEs)
Change in vital signs parameters over time
Measured: Through study completion, an average of 4 years
The Incidence and severity of treatment-emergent adverse events (TEAEs)
Change in laboratory safety parameters over time.
Measured: Through study completion, an average of 4 years
Secondary outcomes (4)
Change in concentrations
Absolute and percent change in the concentrations of Plasma lyso-monosialoganglioside GM1 (Lyso-GM1; for participants with GM1) since the first dose of nizubaglustat
Measured: Through study completion, an average of 4 years
Change in concentrations
Absolute and percent change in the concentrations of Plasma Lyso-GM2 (for participants with GM2) since the first dose of nizubaglustat
Measured: Through study completion, an average of 4 years
Change in concentrations
Absolute and percent change in the concentrations of Plasma N-palmitoyl-O-phosphocholine-serine (PPCS; for participants with NPC) since the first dose of nizubaglustat
Measured: Through study completion, an average of 4 years
Change in concentrations
Absolute and percent change in the concentrations of Glucosylsphingosine (GlcSph; for participants with GD3) since the first dose of nizubaglustat
Measured: Through study completion, an average of 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2026
- Study start10 Dec 2026 (estimated)
- Primary completion1 Apr 2030 (estimated)
- Study completion1 Apr 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Niemann-Pick Disease Type CStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 218 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Azafaros B.V.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07885917
- Sponsor's protocol ID
- AZA-001-302-MI
- Other IDs
- 2026-527156-12-00, 2026-527156-12, Universal Trial Number (UTN)
- Acronym
- HARBOR
- Status last verified
- Oct 2026
- First submitted
- 14 Oct 2026
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Roll-over Trial to Evaluate the Long-term Safety and Tolerability of Nizubaglustat (AZ-3102) in Participants With Rare Lysosomal Disorders Who Have Participated in Previous Nizubaglustat Trials and Wish to Continue Nizubaglustat Treatment
- ClinicalTrials.gov ID
- NCT07885917
- Acronym / sponsor ID
- HARBOR / AZA-001-302-MI
- Conditions
- Niemann-Pick Disease Type C, GM2 Gangliosidosis, GM1 Gangliosidosis, Gaucher Disease Type 3
- Keywords
- NPC, GM1, GM2, GD3, Nizubaglustat, HARBOR, Rare Lysosomal Disorders, AZ-3102
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 218 participants (estimated)
- Lead sponsor
- Azafaros B.V.Industry (pharma, biotech, devices)
- Study start
- 10 Dec 2026 (estimated)
- Primary completion
- 1 Apr 2030 (estimated)
- Study completion
- 1 Apr 2030 (estimated)
- First posted
- 21 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an open-label extension trial to evaluate the long-term safety and tolerability of nizubaglustat (AZ-3102) in participants with rare lysosomal disorders who have participated in a previous nizubaglustat trial and wish to continue nizubaglustat treatment.
Detailed description
This is a multi-center, global, open-label, extension trial in participants with Niemann-Pick disease type C (NPC), GM1 gangliosidosis, GM2 gangliosidosis, or Gaucher disease type 3 (GD3) who previously participated in a clinical trial of nizubaglustat (AZ-3102) and wish to continue treatment. All participants will receive nizubaglustat once daily.
The primary objective is to assess the long-term safety and tolerability of continued daily administration of nizubaglustat. The trial will also investigate the effect of nizubaglustat on disease biomarkers and explore the effect of long-term treatment on neurological aspects of disease progression.
Participants may remain in the trial under marketing authorization has been granted for nizubaglustat in their country or until the sponsor decides to stop the trial.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| All participants will receive nizubaglustat | Experimental | Drug: AZ-3102 |
Who may qualify
- Ages
- 4 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Have participated in a trial of nizubaglustat and wish to continue nizubaglustat treatment
- Participation is considered beneficial by the investigator
- Female participants of childbearing potential who are willing to follow the protocol-defined contraceptive requirements
- Male participants who are willing to follow the protocol-defined contraceptive requirements
Key exclusion criteria (4 listed)
- A positive serum pregnancy test (for women of childbearing potential).
- Any medical event or condition that prevents participation in the trial based on the judgment of the investigator (e.g., severe infection and severe cognitive impairment).
- Use of any other treatment with a similar mode of action to nizubaglustat (GCS or NLGase inhibition), e.g., miglustat or venglustat.
- Participation in another interventional trial or non-interventional study or in an Early Access Program.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AZ-3102Daily oral intake of nizubaglustat (AZ-3102) dispersible tablets | Drug | All participants will receive nizubaglustat |
Primary outcome
The Incidence and severity of treatment-emergent adverse events (TEAEs)
Time frame: Through study completion, an average of 4 years
Change in vital signs parameters over time
The Incidence and severity of treatment-emergent adverse events (TEAEs)
Time frame: Through study completion, an average of 4 years
Change in laboratory safety parameters over time.
4 secondary outcomes
Change in concentrations
Time frame: Through study completion, an average of 4 years
Change in concentrations
Time frame: Through study completion, an average of 4 years
Change in concentrations
Time frame: Through study completion, an average of 4 years
Change in concentrations
Time frame: Through study completion, an average of 4 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Niemann-Pick Disease Type C
RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
Niemann-Pick Type C Disease
RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
Niemann-Pick Type C Disease, GM1 Gangliosidosis
RecruitingObservational study
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
Niemann-Pick Disease, Type C
Active, not recruitingPhase 2
A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
GM2 Gangliosidosis, Niemann-Pick Type C Disease
RecruitingObservational study
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C
Niemann-Pick Disease, Type C
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing AZ-3102 in people with Niemann-Pick Disease Type C and GM2 Gangliosidosis, run by Azafaros B.V..
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Incidence and severity of treatment-emergent adverse events (TEAEs) (time frame: Through study completion, an average of 4 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.